• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by HH&L Acquisition Co.

    2/9/24 4:14:04 PM ET
    $HHLA
    Medical Specialities
    Health Care
    Get the next $HHLA alert in real time by email
    SC 13G 1 HHLA.htm SCHEDULE 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

    (Rule 13d-102)

     

    Under the Securities Exchange Act of 1934

     

    HH&L Acquisition Co

    (Name of Issuer)

     

    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G39714103

    (CUSIP Number)

     

    February 07, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    Rule 13d-1(b)¨
    Rule 13d-1(c)x
    Rule 13d-1(d)¨

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

    (Page 1 of 12 Pages)

     

     
     

     

    CUSIP No.  G39714103 Schedule 13G Page 2 of 12 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    THE K2 Principal Fund, L.P.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ontario, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        298,091

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

     298,091

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        298,091

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.08%

    12

    TYPE OF REPORTING PERSON

    PN

     

      

     
     
    CUSIP No.  G39714103 Schedule 13G Page 3 of 12 Pages

      

    1

    NAME OF REPORTING PERSONS

     

    K2 Genpar 2017 Inc.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ontario, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        298,091

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

     298,091

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        298,091

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.08%

    12

    TYPE OF REPORTING PERSON

    CO

     

     
     
    CUSIP No.  G39714103 Schedule 13G Page 4 of 12 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    SHAWN KIMEL INVESTMENTS, INC.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    ONTARIO, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        298,091

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

        298,091

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

       298,091

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.08%

    12

    TYPE OF REPORTING PERSON

    CO

     

     
     
    CUSIP No.  G39714103 Schedule 13G Page 5 of 12 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    K2 & ASSOCIATES INVESTMENT MANAGEMENT INC.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    ONTARIO, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        298,091

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

        298,091

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

       298,091

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.08%

    12

    TYPE OF REPORTING PERSON

    CO

      

     
     
    CUSIP No.  G39714103 Schedule 13G Page 6 of 12 Pages

      

    Item 1(a).Name of Issuer:

     

    The name of the issuer is HH&L Acquisition Co

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    The Companys principal executive offices are located at Suite 2001-2002, 20/F, York House, The Landmark, 15 Queens Road Central, Central, Hong Kong

     

    Item 2(a).Name of Person Filing:

     

    The persons filing this statement are Shawn Kimel Investments, Inc., an Ontario corporation (“SKI“), The K2 Principal Fund, L.P., an Ontario limited partnership (the “Fund“), K2 Genpar 2017 Inc., an Ontario corporation and the General Partner to the Fund (“Genpar 2017“), and K2 & Associates Investment Management Inc., an Ontario corporation (“K2 & Associates“). Together SKI, the Fund, Genpar2017, and K2 & Associates are the “Reporting Persons“).

     

    Mr.Kimel is President of SKI

    Mr.Sikorski is Secretary of Genpar 2017, and President of K2 & Associates. K2 & Associates is a direct 66.5% owned subsidiary of SKI, and is the investment manager of the Fund

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is 2 Bloor St West, Suite 801, Toronto, Ontario, M4W 3E2

     

    Item 2(c).Citizenship:

     

    Mr.Kimel is a citizen of Canada.

    Mr.Sikorski is a citizen of Canada.

     

    The Fund is an Ontario limited partnership.

     

    Each of SKI and GenPar 2017 Inc and K2 & Associates is an Ontario corporation.

     

    Item 2(d).Title of Class of Securities:

     

    Class A ordinary shares, par value $0.0001 per share

     

    Item 2(e).CUSIP Number:

     

    G39714103

     

     
    CUSIP No.  G39714103 Schedule 13G Page 7 of 12 Pages

      

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨   Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨   Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨   Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e)¨   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨     An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)¨    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

    (j)¨    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:________________.

     

     
     
    CUSIP No.  G39714103 Schedule 13G Page 8 of 12 Pages

      

    Item 4. Ownership:

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The K2 Principal Fund, L.P.

     

    (a) Amount beneficially owned: 298,091
    (b) Percent of class: 7.08%
    (c) Number of shares as to which the person has:

      (i)   Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 298,091
      (iii)   Sole power to dispose or direct the disposition of: 0
      (iv)   Shared power to dispose or direct the disposition of: 298,091

     

    K2 Genpar 2017 Inc.

     

    (a) Amount beneficially owned: 298,091
    (b) Percent of class: 7.08%
    (c) Number of shares as to which the person has:

      (i) Sole power to vote or direct the vote: 0
      (ii) Shared power to vote or direct the vote: 298,091
      (iii) Sole power to dispose or direct the disposition of: 0
      (iv) Shared power to dispose or direct the disposition of: 298,091

     

    SHAWN KIMEL INVESTMENTS, INC.

     

    (a) Amount beneficially owned: 298,091
    (b) Percent of class: 7.08%
    (c) Number of shares as to which the person has:

      (i) Sole power to vote or direct the vote: 0
      (ii) Shared power to vote or direct the vote: 298,091
      (iii) Sole power to dispose or direct the disposition of: 0
      (iv) Shared power to dispose or direct the disposition of: 298,091

     

     

     
    CUSIP No.  G39714103 Schedule 13G Page 9 of 12 Pages

      

    K2 & Associates Investment Management Inc..

     

    (a) Amount beneficially owned: 298,091
    (b) Percent of class: 7.08%
    (c) Number of shares as to which the person has:

      (i) Sole power to vote or direct the vote: 0
      (ii) Shared power to vote or direct the vote: 298,091
      (iii) Sole power to dispose or direct the disposition of: 0
      (iv) Shared power to dispose or direct the disposition of: 298,091

     

    298,091 Class A ordinary shares, par value $0.0001 per share held of record (and may be deemed to be beneficially owned) by The K2 Principal Fund, L.P. See Item 2(a) above for a description of the corporate structure of the Reporting Persons. Each of the Reporting Persons may be deemed to be beneficial owners of the 298,091 shares of the Issuer's Class A ordinary shares, par value $0.0001 per share that are held by The K2 Principal Fund, L.P. Mr.Kimel is President of SKI. Mr. Todd Sikorki is Secretary of GenPar 2017 and President of K2 & ASSOCIATES, and exercises ultimate voting and investment powers over the 298,091 shares of the Issuer's Units that are held of record by The K2 Principal Fund, L.P

     

    The percentages used in this Schedule 13G are calculated based upon 4,205,185 ordinary shares issued and outstanding as of November 20, 2023, as reported in the companies 10-Q filed with the SEC on November 20, 2023.

     

    Item 5.         Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]

     

    Item 6.         Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.         Identification and Classification of Members of the Group.

     

    Not applicable.

     

     
     

     

    CUSIP No.  G39714103 Schedule 13G Page 10 of 12 Pages

     

    Item 9.         Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.        Certification.

     

    Each of the Reporting Persons hereby makes the following certification:

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No.  G39714103 Schedule 13G Page 11 of 12 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 09, 2024

      THE K2 PRINCIPAL FUND, L.P.
         
      By: K2 Genpar 2017 Inc., its General Partner
         
      By: /s/ Todd Sikorki
        Todd Sikorki
        Secretary
         
         
      K2 Genpar 2017 Inc.
         
      By: /s/ Todd Sikorki
        Todd Sikorki
        Secretary
         
      SHAWN KIMEL INVESTMENTS, INC.
         
      By: /s/ Shawn Kimel
        Shawn Kimel
        President
         
         
      /s/ Todd Sikorki
      K2 & ASSOCIATES INVESTMENT MANAGEMENT INC.
         
      By: /s/ Todd Sikorki
        Todd Sikorki
        President
         

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    CUSIP No.  G39714103 Schedule 13G Page 12 of 12 Pages

     

    Exhibit 1

     

    JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 09, 2024

      THE K2 PRINCIPAL FUND, L.P.
         
      By: K2 Genpar 2017 Inc., its General Partner
         
      By: /s/ Todd Sikorki
        Todd Sikorki
        Secretary
         
         
      K2 Genpar 2017 Inc.
         
      By: /s/ Todd Sikorki
        Todd Sikorki
        Secretary
         
      SHAWN KIMEL INVESTMENTS, INC.
         
      By: /s/Shawn Kimel
        Shawn Kimel
        President
         
         
      K2 & ASSOCIATES INVESTMENT MANAGEMENT INC.
         
      By: /s/ Todd Sikorki
        Todd Sikorki
        President
         
         
    Get the next $HHLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HHLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HHLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

      PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta's leadership and commitment to excellence. "This CAP Accreditation is a tremendous accomplishment that signifies DiaCarta's commitment to excellence and I am proud of our team's dedication in support this major milestone," said Zheng 

      5/9/23 5:51:25 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

      Abstracts demonstrating XNA technology's improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technology's potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to

      4/16/23 2:00:00 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

      PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection. The test is designed for use by authorized laboratories on the most popular qPCR instruments, including the Thermo Fisher (ABI) QuantStudio5, Thermo Fisher (ABI) 7500 Fast Dx, Bio-Rad CFX384, and Roche LightCycler 480 II Systems. QuantiVirusTM MPXV test targets two di

      1/12/23 8:30:00 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by HH&L Acquisition Co.

      25-NSE - HH&L Acquisition Co. (0001824185) (Subject)

      2/23/24 10:50:57 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • HH&L Acquisition Co. filed SEC Form 8-K: Other Events

      8-K - HH&L Acquisition Co. (0001824185) (Filer)

      2/7/24 11:57:39 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by HH&L Acquisition Co.

      PRE 14A - HH&L Acquisition Co. (0001824185) (Filer)

      1/23/24 5:14:45 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highbridge Capital Management Llc sold $2,687,500 worth of Class A Ordinary Shares (250,000 units at $10.75) (SEC Form 4)

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      1/12/24 4:15:16 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 500,000 units of Class A Ordinary Shares

      3 - HH&L Acquisition Co. (0001824185) (Issuer)

      8/15/23 4:30:21 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 4 filed by HH&L Investment Co.

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      5/19/21 11:16:35 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/14/24 5:09:41 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/13/24 8:00:58 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

      SC 13G/A - HH&L Acquisition Co. (0001824185) (Subject)

      2/12/24 4:26:19 PM ET
      $HHLA
      Medical Specialities
      Health Care